본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Japanese journal of clinical oncology v.47 no.1, 2017년, pp.54 - 60   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Ishizawa, Kenichi (Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi ); Fukuhara, Noriko (Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi ); Nakaseko, Chiaki (Department of Hematology, Chiba University Graduate School of Medicine, Chiba ); Chiba, Shigeru (Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki ); Ogura, Michinori (Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi ); Okamoto, Akihiko (Sanofi K.K., Shinjuku-ku, Tokyo ); Sunaga, Yoshinori (Sanofi K.K., Shinjuku-ku, Tokyo ); Tobinai, Kensei (Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan );
  • 초록  

    The overseas dosage of alemtuzumab 30 mg by intravenous infusion every other day three times a week for 12 weeks is safe and effective similarly in Japanese B-CLL patients. Objective To evaluate the safety, efficacy and pharmacokinetics of alemtuzumab in Japanese patients, we conducted a phase I study in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Methods Six patients received alemtuzumab by intravenous infusion every other day three times a week for 12 weeks. The dose was gradually escalated on daily basis (3, 10 and then 30 mg) until the patient tolerated. The primary objective was to evaluate the safety of alemtuzumab in Japanese patients and the secondary objectives were to evaluate the overall response rate and the pharmacokinetics. Results The major treatment-emergent adverse events were anemia, neutropenia (6/6 patients each) and thrombocytopenia (5/6 patients) in hematologic adverse events, and nausea, vomiting, decreased appetite, cytomegalovirus test positive and pyrexia (4/6 patients) in non-hematologic adverse events. As serious adverse events, cytomegalovirus infection, pulmonary tuberculosis and diffuse large B-cell lymphoma were reported in 1/6 patient each. The overall response rate was 33% (95% confidence interval: 4–78) (1/6 patient each achieved complete response and partial response, respectively) and 3/6 patients had stable disease and 1/6 patient had progressive disease. The median time to response was 2.9 months. After last intravenous dosing (Week 12) of alemtuzumab 30 mg every other day three times a week, C max , t max , AUC 0−τ and t 1/2 were higher and CL and V ss were lower than the values observed after the first dose. Conclusions The efficacy, safety and pharmacokinetics results observed with alemtuzumab in Japanese patients were generally similar to those reported in overseas clinical studies. Alemtuzumab at 30 mg by intravenous infusion every other day three times a week for 12 weeks should be safe and effective similarly in Japanese B-cell chronic lymphocytic leukemia patients. Clinical trial registration no. NCT00923182.


  • 주제어

    relapsed or refractory B-CLL .   alemtuzumab .   efficacy .   safety .   pharmacokinetics.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기